Exact Mass: 558.1678

Exact Mass Matches: 558.1678

Found 27 metabolites which its exact mass value is equals to given mass value 558.1678, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Physalin K

2,19-dihydroxy-13,16,23-trimethyl-6,10,17,26,27,30-hexaoxanonacyclo[23.2.2.1⁵,¹⁴.1⁵,¹⁵.0¹,²³.0⁴,²².0⁸,¹³.0¹¹,¹⁶.0¹⁵,¹⁹]hentriacont-28-ene-9,18,24,31-tetrone

C28H30O12 (558.1737)


Physalin Q is found in fruits. Physalin Q is a constituent of Physalis alkekengi (winter cherry). Constituent of Physalis alkekengi (winter cherry). Physalin Q is found in fruits.

   

6-O-acetyl amurensin

6-O-acetyl amurensin

C28H30O12 (558.1737)


   

arimetamycin C

arimetamycin C

C28H30O12 (558.1737)


   

isoplagiochin G

isoplagiochin G

C35H26O7 (558.1678)


   

DTXSID20941729

DTXSID20941729

C28H30O12 (558.1737)


   

Pillaromycin A

Pillaromycin A

C28H30O12 (558.1737)


   
   

Physalin K

2,19-dihydroxy-13,16,23-trimethyl-6,10,17,26,27,30-hexaoxanonacyclo[23.2.2.1^{5,14}.1^{5,15}.0^{1,23}.0^{4,22}.0^{8,13}.0^{11,16}.0^{15,19}]hentriacont-28-ene-9,18,24,31-tetrone

C28H30O12 (558.1737)


   

(7S,11S,13S,20R)-3,17,19-trihydroxy-23-(5-hydroxy-6-methyloxan-2-yl)oxy-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.02,18.04,16.06,14.07,11]tricosa-2(18),3,6(14),16-tetraene-5,9,15-trione

(7S,11S,13S,20R)-3,17,19-trihydroxy-23-(5-hydroxy-6-methyloxan-2-yl)oxy-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.02,18.04,16.06,14.07,11]tricosa-2(18),3,6(14),16-tetraene-5,9,15-trione

C28H30O12 (558.1737)


   
   
   

Tarafenacin (D-tartrate)

Tarafenacin (D-tartrate)

C25H26F4N2O8 (558.1625)


Tarafenacin D-tartrate (SVT-40776 D-tartrate) is a highly selective M3 muscarinic receptor antagonist (Ki= 0.19 nM), ~200 fold selectivity over M2 receptor. IC50 value: 0.19 nM (Ki) [1] Target: M3 muscarinic receptor in vitro: SVT-40776 is highly selective for M(3) over M(2) receptors (Ki = 0.19 nmol.L(-1) for M(3) receptor affinity). SVT-40776 was the most potent in inhibiting carbachol-induced bladder contractions of the anti-cholinergic agents tested, without affecting atrial contractions over the same range of concentrations. SVT-40776 exhibited the highest urinary versus cardiac selectivity (199-fold) [1]. SVT-40776 has a much higher binding affinity (K(d) = 0.4 nM) to M5 mAChR than that of solifenacin (K(d) = 31 nM) with the same reeptor. The calculated binding free energy change (-2.3 ± 0.3 kcal/mol) from solifenacin to SVT-40776 is in good agreement with the experimentally derived binding free energy change (-2.58 kcal/mol), suggesting that our modeled M5 mAChR structure and its complexes with the antagonists are reliable [2]. in vivo: In the guinea pig in vivo model, SVT-40776 inhibited 25\% of spontaneous bladder contractions at a very low dose (6.97 microg.kg(-1) i.v), without affecting arterial blood pressure [1].

   

(7s,11s,13s,20r)-3,17,19-trihydroxy-23-[(5-hydroxy-6-methyloxan-2-yl)oxy]-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2,4(16),6(14),17-tetraene-5,9,15-trione

(7s,11s,13s,20r)-3,17,19-trihydroxy-23-[(5-hydroxy-6-methyloxan-2-yl)oxy]-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2,4(16),6(14),17-tetraene-5,9,15-trione

C28H30O12 (558.1737)


   

(1r,2r,4r,5r,8s,11r,13s,14s,15r,16s,19s,22s,23r,25s)-2,19-dihydroxy-13,16,23-trimethyl-6,10,17,26,27,30-hexaoxanonacyclo[23.2.2.1⁵,¹⁴.1⁵,¹⁵.0¹,²³.0⁴,²².0⁸,¹³.0¹¹,¹⁶.0¹⁵,¹⁹]hentriacont-28-ene-9,18,24,31-tetrone

(1r,2r,4r,5r,8s,11r,13s,14s,15r,16s,19s,22s,23r,25s)-2,19-dihydroxy-13,16,23-trimethyl-6,10,17,26,27,30-hexaoxanonacyclo[23.2.2.1⁵,¹⁴.1⁵,¹⁵.0¹,²³.0⁴,²².0⁸,¹³.0¹¹,¹⁶.0¹⁵,¹⁹]hentriacont-28-ene-9,18,24,31-tetrone

C28H30O12 (558.1737)


   

6'''-o-acetylamurensin

NA

C28H30O12 (558.1737)


{"Ingredient_id": "HBIN012593","Ingredient_name": "6'''-o-acetylamurensin","Alias": "NA","Ingredient_formula": "C28H30O12","Ingredient_Smile": "CC(=CCC1=C(C=C(C2=C1OC(=C(C2=O)O)C3=CC=C(C=C3)O)O)OC4C(C(C(C(O4)COC(=O)C)O)O)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "315","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

(1s,2r,4r,5r,8s,11r,13s,14s,15r,16s,19s,22s,23r,25r)-2,19-dihydroxy-13,16,23-trimethyl-6,10,17,26,27,30-hexaoxanonacyclo[23.2.2.1⁵,¹⁴.1⁵,¹⁵.0¹,²³.0⁴,²².0⁸,¹³.0¹¹,¹⁶.0¹⁵,¹⁹]hentriacont-28-ene-9,18,24,31-tetrone

(1s,2r,4r,5r,8s,11r,13s,14s,15r,16s,19s,22s,23r,25r)-2,19-dihydroxy-13,16,23-trimethyl-6,10,17,26,27,30-hexaoxanonacyclo[23.2.2.1⁵,¹⁴.1⁵,¹⁵.0¹,²³.0⁴,²².0⁸,¹³.0¹¹,¹⁶.0¹⁵,¹⁹]hentriacont-28-ene-9,18,24,31-tetrone

C28H30O12 (558.1737)


   

[(2r,3s,4s,5r,6s)-6-{[3,5-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxochromen-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6s)-6-{[3,5-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxochromen-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C28H30O12 (558.1737)


   

(2s,3s,4r)-2,5,7-trihydroxy-4-{[(2s,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3,9-dimethoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione

(2s,3s,4r)-2,5,7-trihydroxy-4-{[(2s,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3,9-dimethoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione

C28H30O12 (558.1737)


   

4-[(4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl)oxy]-2,5-dihydroxy-3,9-dimethoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione

4-[(4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl)oxy]-2,5-dihydroxy-3,9-dimethoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione

C28H30O12 (558.1737)


   

5,15,19-trihydroxy-23-[(5-hydroxy-6-methyloxan-2-yl)oxy]-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2(18),4(16),5,14-tetraene-3,9,17-trione

5,15,19-trihydroxy-23-[(5-hydroxy-6-methyloxan-2-yl)oxy]-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2(18),4(16),5,14-tetraene-3,9,17-trione

C28H30O12 (558.1737)


   

(6-{[3,5-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxochromen-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methyl acetate

(6-{[3,5-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxochromen-7-yl]oxy}-3,4,5-trihydroxyoxan-2-yl)methyl acetate

C28H30O12 (558.1737)


   
   

(1r,7s,11s,13s,19r,20r,23r)-3,17,19-trihydroxy-23-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2(18),3,6(14),16-tetraene-5,9,15-trione

(1r,7s,11s,13s,19r,20r,23r)-3,17,19-trihydroxy-23-{[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy}-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2(18),3,6(14),16-tetraene-5,9,15-trione

C28H30O12 (558.1737)


   

3,17,19-trihydroxy-23-[(5-hydroxy-6-methyloxan-2-yl)oxy]-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2(18),3,6(14),16-tetraene-5,9,15-trione

3,17,19-trihydroxy-23-[(5-hydroxy-6-methyloxan-2-yl)oxy]-13,20-dimethyl-8,12,21-trioxahexacyclo[17.2.2.0²,¹⁸.0⁴,¹⁶.0⁶,¹⁴.0⁷,¹¹]tricosa-2(18),3,6(14),16-tetraene-5,9,15-trione

C28H30O12 (558.1737)


   

(2s,3r,4s)-4-{[(2s,3s,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-2,5-dihydroxy-3,9-dimethoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione

(2s,3r,4s)-4-{[(2s,3s,4r,5r,6s)-4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl]oxy}-2,5-dihydroxy-3,9-dimethoxy-2-methyl-3,4-dihydrotetracene-1,6,11-trione

C28H30O12 (558.1737)


   

(7z)-16-(3-hydroxybenzoyl)-14-oxapentacyclo[21.3.1.1²,⁶.1⁹,¹³.0¹⁵,²⁰]nonacosa-1(27),2(29),3,5,7,9(28),10,12,15(20),16,18,23,25-tridecaene-3,18,19,26-tetrol

(7z)-16-(3-hydroxybenzoyl)-14-oxapentacyclo[21.3.1.1²,⁶.1⁹,¹³.0¹⁵,²⁰]nonacosa-1(27),2(29),3,5,7,9(28),10,12,15(20),16,18,23,25-tridecaene-3,18,19,26-tetrol

C35H26O7 (558.1678)